EG25683A - Benzoxazine derivatives and uses thereof - Google Patents

Benzoxazine derivatives and uses thereof

Info

Publication number
EG25683A
EG25683A EG2003050432A EG2003050432A EG25683A EG 25683 A EG25683 A EG 25683A EG 2003050432 A EG2003050432 A EG 2003050432A EG 2003050432 A EG2003050432 A EG 2003050432A EG 25683 A EG25683 A EG 25683A
Authority
EG
Egypt
Prior art keywords
benzoxazine derivatives
benzoxazine
derivatives
Prior art date
Application number
EG2003050432A
Other languages
English (en)
Inventor
Jacob Berger
Robin D Clark
Shu-Hai Zhao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of EG25683A publication Critical patent/EG25683A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
EG2003050432A 2002-05-13 2003-05-10 Benzoxazine derivatives and uses thereof EG25683A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37800302P 2002-05-13 2002-05-13

Publications (1)

Publication Number Publication Date
EG25683A true EG25683A (en) 2012-05-16

Family

ID=29420358

Family Applications (1)

Application Number Title Priority Date Filing Date
EG2003050432A EG25683A (en) 2002-05-13 2003-05-10 Benzoxazine derivatives and uses thereof

Country Status (37)

Country Link
US (4) US6867204B2 (fr)
EP (1) EP1506179B1 (fr)
JP (1) JP4307377B2 (fr)
KR (1) KR100636475B1 (fr)
CN (1) CN100429206C (fr)
AR (1) AR039988A1 (fr)
AT (1) ATE316523T1 (fr)
AU (1) AU2003233231B2 (fr)
BR (1) BRPI0310032B8 (fr)
CA (1) CA2485136C (fr)
DE (1) DE60303376T2 (fr)
DK (1) DK1506179T3 (fr)
EA (1) EA009982B1 (fr)
EC (1) ECSP045420A (fr)
EG (1) EG25683A (fr)
ES (1) ES2256744T3 (fr)
GT (1) GT200300108A (fr)
HK (1) HK1080846A1 (fr)
HR (1) HRP20041030B1 (fr)
IL (1) IL164928A0 (fr)
JO (1) JO2413B1 (fr)
MA (1) MA27118A1 (fr)
MX (1) MXPA04011254A (fr)
MY (1) MY139612A (fr)
NO (1) NO329380B1 (fr)
NZ (1) NZ536230A (fr)
PA (1) PA8573501A1 (fr)
PE (1) PE20040757A1 (fr)
PL (1) PL211057B1 (fr)
PT (1) PT1506179E (fr)
RS (1) RS51042B (fr)
TN (1) TNSN04225A1 (fr)
TW (1) TWI258479B (fr)
UA (1) UA76877C2 (fr)
UY (1) UY27803A1 (fr)
WO (1) WO2003095434A1 (fr)
ZA (1) ZA200408783B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1408976B3 (fr) 2001-07-20 2010-08-25 Psychogenics Inc. Traitement des troubles de deficit de l'attention/hyperactivite
PT1497266E (pt) 2002-03-27 2008-09-10 Glaxo Group Ltd Derivados de quinolina e sua utilização como ligandos 5-ht6
ATE316523T1 (de) * 2002-05-13 2006-02-15 Hoffmann La Roche Benzoxazinderivate als 5-ht6-modulatoren und deren verwendungen
MXPA05004758A (es) 2002-11-08 2005-08-02 Hoffmann La Roche Benzoxazinonas sustituidas y uso de las mismas.
MXPA06000795A (es) 2003-07-22 2006-08-23 Arena Pharm Inc Derivados de diaril y arilheteroaril urea como moduladores del receptor 5-ht2a de serotonina utiles para la profilaxis y tratamiento de desordenes relacionados con el mismo.
AU2004299201B2 (en) 2003-12-09 2009-12-03 F. Hoffmann-La Roche Ag Benzoxazine derivatives and uses thereof
BRPI0506909A (pt) * 2004-01-16 2007-05-29 Hoffmann La Roche derivados de 1-benzil-5piperazin-1-il-3,4 diidro-1h-quinazolin-2-ona e os respectivos derivados de 1h-benzo (1,2,6) tiadiazina-2,2-dióxido e 1,4-diidro-benzo (d) (1,3)oxazin-2-ona como moduladores do receptor de 5-hidroxitriptamina (5-ht) para o tratamento de doenças do sistema nervoso central
RU2372344C2 (ru) * 2004-05-05 2009-11-10 Ф. Хоффманн-Ля Рош Аг Арилсульфонилбензодиоксаны, применяемые для модуляции 5-нт6 рецептора, 5-нт2a рецептора или и того, и другого
US7378415B2 (en) * 2004-09-30 2008-05-27 Roche Palo Alto Llc Benzoxazine and quinoxaline derivatives and uses thereof
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
JP4975626B2 (ja) * 2004-09-30 2012-07-11 エフ．ホフマン−ラ ロシュ アーゲー 認知障害の処置用の組成物および方法
BRPI0516754A (pt) * 2004-09-30 2008-09-16 Hoffmann La Roche usos e derivados de benzoxazina e quinoxalina
EP2508177A1 (fr) 2007-12-12 2012-10-10 Glaxo Group Limited Associations contenant de la 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (fr) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Procédés de préparation de dérivés de pyrazole utiles comme modulateurs du récepteur de la sérotonine 5-ht<sb>2a</sb>
WO2010062321A1 (fr) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Procédés utiles pour la préparation de 1-[3-(4-bromo-2-méthyl-2h-pyrazol-3-yl)-4-méthoxy-phényl]-3-(2,4-difluoro‑phényl)-urée, et formes cristallines associées
AR078770A1 (es) * 2009-10-27 2011-11-30 Elara Pharmaceuticals Gmbh Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas.
KR101293384B1 (ko) * 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
US9403800B2 (en) * 2012-01-24 2016-08-02 Chemregen, Inc. Compounds for inhibition of cancer cell proliferation
CA2935944A1 (fr) 2014-01-09 2015-07-16 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Benzoxazine substituee et composes associes
EP4119141A1 (fr) 2015-06-12 2023-01-18 Axovant Sciences GmbH Nelotanserin pour la prophylaxie et le traitement d'un trouble du comportement en sommeil paradoxal
CA2992518A1 (fr) 2015-07-15 2017-01-19 Axovant Sciences Gmbh Derives d'arylheretoaryl uree en tant que modulateurs du recepteur serotoninergique 5-ht2a utiles pour la prophylaxie et le traitement d'hallucinations associees a une maladie neurodegenerative

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1029479C (zh) * 1989-11-08 1995-08-09 山之内制药株式会社 新型苯并噁嗪衍生物的制备方法
US5492914A (en) * 1994-07-28 1996-02-20 Syntex (U.S.A.) Inc. 2-(1-azabicyclo[2.2.2]oct-3 s-yl)-6-hydroxy-2,4,5,6-tetrahydro-1H-benz[DE]is[2.2.2]oct-3's-yl)-6-hydroxy-2,3,3a,4,5,6-hexahydro-1h-benz [DE]isoquinolin-1-one and individual stereoisomers thereof
GB9507203D0 (en) 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
IL132409A0 (en) 1997-04-18 2001-03-19 Smithkline Beecham Plc Indole derivatives having combined 5ht1a 5ht1b and 5ht1d receptor antagonist activity
US6316450B1 (en) 1997-07-11 2001-11-13 Smithkline Beecham P.L.C. Compounds
ES2206963T3 (es) * 1997-07-25 2004-05-16 H. Lundbeck A/S Derivados de indol y de 2,3-dihidroindol, su preparacion y uso.
GB9801392D0 (en) 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
JP2003521443A (ja) * 1998-06-19 2003-07-15 ハー・ルンドベック・アクチエゼルスカベット ４，５，６及び７−インドール及びインドリン誘導体、その製造方法及びその使用方法
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
JP4919565B2 (ja) * 1999-08-23 2012-04-18 アボツト・ヘルスケア・プロダクツ・ベー・ブイ 新規なフェニルピペラジン
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
EP1255743A1 (fr) 2000-02-01 2002-11-13 Millenium Pharmaceuticals, Inc. 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINES UTILISEES COMME INHIBITEURS DU FACTEUR Xa
ATE316523T1 (de) * 2002-05-13 2006-02-15 Hoffmann La Roche Benzoxazinderivate als 5-ht6-modulatoren und deren verwendungen

Also Published As

Publication number Publication date
EP1506179B1 (fr) 2006-01-25
PT1506179E (pt) 2006-06-30
BR0310032A (pt) 2005-02-15
PE20040757A1 (es) 2004-11-06
UA76877C2 (uk) 2006-09-15
RS97004A (en) 2006-10-27
ES2256744T3 (es) 2006-07-16
NZ536230A (en) 2007-05-31
EA200401455A1 (ru) 2005-06-30
EA009982B1 (ru) 2008-04-28
JP4307377B2 (ja) 2009-08-05
US20130123251A1 (en) 2013-05-16
TW200400188A (en) 2004-01-01
HK1080846A1 (en) 2006-05-04
ECSP045420A (es) 2005-01-03
US6867204B2 (en) 2005-03-15
DE60303376T2 (de) 2006-11-16
WO2003095434A1 (fr) 2003-11-20
JP2005530774A (ja) 2005-10-13
TNSN04225A1 (fr) 2007-03-12
CN100429206C (zh) 2008-10-29
ATE316523T1 (de) 2006-02-15
HRP20041030B1 (hr) 2013-03-31
PL374019A1 (en) 2005-09-19
KR20040106538A (ko) 2004-12-17
AR039988A1 (es) 2005-03-09
CA2485136A1 (fr) 2003-11-20
BRPI0310032B8 (pt) 2021-05-25
US20050130962A1 (en) 2005-06-16
TWI258479B (en) 2006-07-21
UY27803A1 (es) 2003-11-28
MA27118A1 (fr) 2004-12-20
CA2485136C (fr) 2011-12-20
HRP20041030A2 (en) 2005-06-30
IL164928A0 (en) 2005-12-18
DK1506179T3 (da) 2006-06-06
US8377931B2 (en) 2013-02-19
BRPI0310032B1 (pt) 2019-01-08
GT200300108A (es) 2004-03-15
MY139612A (en) 2009-10-30
NO20044665L (no) 2004-12-03
KR100636475B1 (ko) 2006-10-18
AU2003233231B2 (en) 2009-02-26
ZA200408783B (en) 2005-12-28
US20030232825A1 (en) 2003-12-18
AU2003233231A1 (en) 2003-11-11
US20090325950A1 (en) 2009-12-31
NO329380B1 (no) 2010-10-04
PL211057B1 (pl) 2012-04-30
PA8573501A1 (es) 2003-12-10
MXPA04011254A (es) 2005-01-25
EP1506179A1 (fr) 2005-02-16
CN1653054A (zh) 2005-08-10
RS51042B (sr) 2010-10-31
JO2413B1 (en) 2007-11-11
DE60303376D1 (de) 2006-04-13

Similar Documents

Publication Publication Date Title
IL175817A0 (en) Benzoxazine derivatives and uses thereof
AU2003266321A1 (en) Tetrahydropyrimidine-2-one derivatives and their uses
EG25683A (en) Benzoxazine derivatives and uses thereof
EP1539941A4 (fr) Adzymes et leurs utilisations
AP1850A (en) Spiroindolineplperidine derivatives
HK1111417A1 (en) Quinazoline derivatives
GB0215823D0 (en) Quinazoline derivatives
IL166100A0 (en) 7,8,9-10-tetrahydro-6h-azepino,6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrroloÄ2,1-bÜ quinazolinone derivatives
IL174479A0 (en) Hemiasterlin derivatives and uses thereof
IL163868A0 (en) Hermiasterlin derivatives and uses thereof
PL377770A1 (pl) Podstawione benzoksazynony i ich zastosowanie
SI1551805T1 (sl) Substituirani gama-fenil-delta-laktami in njihova uporaba
AU2003299943A1 (en) Heterocycles and uses thereof
IL165112A0 (en) Variant integrinpolypeptides and thereof
AU2003281691A1 (en) Furoisoquinoline derivative and use thereof
EP1553101A4 (fr) Derives de n-acetylglucosamine et utilisation
AU2003231827A8 (en) Pseudo-tissues and uses thereof
AU2003298739A8 (en) Intermedin and its uses
GB0316910D0 (en) Fluorocombretastatin and derivatives thereof
AU2003281698A8 (en) 1-phenylpiperidin-3-one derivatives and processes for the preparation thereof
AU2003302173A8 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
PL374817A1 (en) Quinazoline derivatives
GB0220776D0 (en) FOXP2 and uses thereof
HUP0600155A2 (en) Early inflorescence-preferred regulatory elements and uses thereof
GB0307231D0 (en) 7-Nitroindoline derivatives and their uses